Scilex Holding (NASDAQ:SCLX - Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as $5.90 and last traded at $6.12, with a volume of 344459 shares. The stock had previously closed at $6.92.
Analysts Set New Price Targets
Several brokerages have recently issued reports on SCLX. D. Boral Capital reiterated a "hold" rating on shares of Scilex in a report on Friday, April 11th. D Boral Capital downgraded Scilex from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Scilex has a consensus rating of "Moderate Buy" and a consensus target price of $455.00.
View Our Latest Report on SCLX
Scilex Trading Down 17.3 %
The company has a market cap of $27.04 million, a P/E ratio of -4.62 and a beta of 1.04. The firm has a 50-day moving average of $9.56 and a 200 day moving average of $17.36.
Scilex (NASDAQ:SCLX - Get Free Report) last issued its quarterly earnings data on Friday, January 17th. The company reported ($6.30) EPS for the quarter. On average, equities analysts predict that Scilex Holding will post -0.57 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in shares of Scilex by 28.7% in the 4th quarter. Janus Henderson Group PLC now owns 687,547 shares of the company's stock worth $293,000 after buying an additional 153,245 shares during the last quarter. RA Capital Management L.P. lifted its position in shares of Scilex by 296.7% during the fourth quarter. RA Capital Management L.P. now owns 1,036,218 shares of the company's stock worth $442,000 after acquiring an additional 775,039 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Scilex by 965.8% in the fourth quarter. Jane Street Group LLC now owns 321,480 shares of the company's stock valued at $137,000 after acquiring an additional 291,316 shares during the period. Northern Trust Corp raised its position in shares of Scilex by 64.0% in the fourth quarter. Northern Trust Corp now owns 1,273,968 shares of the company's stock worth $543,000 after buying an additional 497,182 shares in the last quarter. Finally, Norges Bank bought a new position in Scilex in the fourth quarter valued at $204,000. 69.67% of the stock is owned by institutional investors.
About Scilex
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
See Also
Before you consider Scilex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.
While Scilex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
